-
公开(公告)号：US09416170B2
公开(公告)日：2016-08-16
申请号：US13757664
申请日：2013-02-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jonathan Davis , Dasa Lipovsek , Ray Camphausen
CPC classification number: C07K14/78 , A61K38/00 , C07K14/47 , C07K16/241 , C07K16/244 , C07K16/28 , C07K16/2833 , C07K16/2857 , C07K2317/92 , C07K2318/20 , C12N15/1062 , C40B40/10 , G01N33/68 , G01N33/6887
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
-
32.发明授权公开(公告)号：US08993265B2
公开(公告)日：2015-03-31
申请号：US14275542
申请日：2014-05-12
Applicant: Bristol-Myers Squibb Company
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Martin J. Corbett , Alexander T. Kozhich
IPC: C07H21/02 , C07H21/04 , C12P21/06 , C12N1/20 , C12N15/00 , C07K14/78 , C07K16/46 , A61K38/39 , A61K47/48 , A61K45/06 , G01N33/74 , C07K14/435 , C07K14/765 , C07K14/79 , C07K16/18
CPC classification number: A61K38/39 , A61K38/00 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , C07K2319/30 , C07K2319/31 , G01N33/74
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
Abstract translation: 本发明涉及结合肌生成抑制素的基于纤连蛋白的支架结构域蛋白。 本发明还涉及这些蛋白质用于治疗肌营养不良症，恶病质，肌肉减少症，骨关节炎，骨质疏松症，糖尿病，肥胖症，COPD，慢性肾脏疾病，心力衰竭，心肌梗死和纤维化的治疗应用中的用途。 本发明还涉及包含这种蛋白质的细胞，编码这种蛋白质或其片段的多核苷酸，以及包含编码蛋白质的多核苷酸的载体。
-
33.发明授权公开(公告)号：US08853154B2
公开(公告)日：2014-10-07
申请号：US14025307
申请日：2013-09-12
Applicant: Bristol-Myers Squibb Company
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Hui Wei , Aaron P. Yamniuk , Vidhyashankar Ramamurthy , Alexander T. Kozhich , Martin J. Corbett , Stanley Richard Krystek, Jr.
IPC: A61K38/00 , A61P3/04 , A61K38/28 , A61P5/50 , A61P3/10 , A61P7/12 , A61P35/00 , C07K1/00 , C07K14/00 , C07K16/00 , C07K17/00 , C07H21/04 , G01N33/00 , C12N1/20 , C12N1/00 , C12P21/06 , C12N15/00 , C12N5/07 , C12N5/10 , C12N5/071 , G01N33/566 , A61K45/06 , C07K14/435 , A61K38/39 , C07K16/46 , G01N33/74 , A61K47/48 , C07K14/78
CPC classification number: A61K38/39 , A61K38/00 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , C07K2319/30 , C07K2319/31 , G01N33/74
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
Abstract translation: 本发明涉及结合肌生成抑制素的基于纤连蛋白的支架结构域蛋白。 本发明还涉及这些蛋白质用于治疗肌营养不良症，恶病质，肌肉减少症，骨关节炎，骨质疏松症，糖尿病，肥胖症，COPD，慢性肾脏疾病，心力衰竭，心肌梗死和纤维化的治疗应用中的用途。 本发明还涉及包含这种蛋白质的细胞，编码这种蛋白质或其片段的多核苷酸，以及包含编码蛋白质的多核苷酸的载体。
-
公开(公告)号：US12194110B2
公开(公告)日：2025-01-14
申请号：US17483393
申请日：2021-09-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , David Donnelly , Dasa Lipovsek , Jochem Gokemeijer , Maria N. Jure-Kunkel , David Fabrizio , Martin C. Wright , Douglas Dischino , Samuel J. Bonacorsi, Jr. , Ralph Adam Smith , Virginie Lafont , Daniel Cohen
Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
-
公开(公告)号：US20220331402A1
公开(公告)日：2022-10-20
申请号：US17721569
申请日：2022-04-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
Patent Agency Ranking
公开(公告)号：US11447538B2
公开(公告)日：2022-09-20
申请号：US16740248
申请日：2020-01-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Dasa Lipovsek , Jonathan H. Davis
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
-
公开(公告)号：US11434275B2
公开(公告)日：2022-09-06
申请号：US16748085
申请日：2020-01-21
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Stanley Richard Krystek, Jr. , Tracy S. Mitchell , Michael L. Gosselin , Dasa Lipovsek , Juhi Juneja
IPC: C07K14/78 , C07K14/765 , C12N15/85
Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
-
公开(公告)号：US20220204589A1
公开(公告)日：2022-06-30
申请号：US17527238
申请日：2021-11-16
Applicant: Bristol-Myers Squibb Company
Inventor： Tracy S. MITCHELL , Michael L. Gosselin , Dasa Lipovsek , Rex Parker , Ray Camphausen , Jonathan H. Davis , David Fabrizio
Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
-
39.发明授权公开(公告)号：US11224634B2
公开(公告)日：2022-01-18
申请号：US17198939
申请日：2021-03-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
40.发明授权公开(公告)号：US11185570B2
公开(公告)日：2021-11-30
申请号：US16287342
申请日：2019-02-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
-
-
-
-
-
-
-
-
Search Results
67
records
(took 0.028 seconds)
